Hutchmed Share News (HCM)

Hutchinson China Begins In-Human Trial Of Novel Inhibitor HMPL-453

Hutchison China Starts Phase One HMPL-523 Trials In China

DIRECTOR DEALINGS SUMMARY: Hutchison China Chair Buys US-Listed ADSs

DIRECTOR DEALINGS: Hutchison China Chairman Buys US-Listed ADSs

DIRECTOR DEALINGS: Hutchison China Non-Executive Sells 10,000 Shares

Hutchison China MediTech presents promising data in Washington

(ShareCast News) - Hutchison China MediTech presented data from a recent Phase I, first-in-human, dose escalating study of the safety, tolerability and pharmacokinetics and pharmacodynamics of single and multiple doses of HMPL-523 on Monday, to the Annual Meeting of the American College of Rheumatol

Hutchison China's JV receives $60m land compensation

(ShareCast News) - Hutchison China MediTech's prescription drug joint-venture received $59.5m on Friday from the Shanghai government under its land compensation agreement. The joint-venture with a subsidiary of Shanghai Pharmaceuticals, Shanghai Hutchison Pharmaceuticals, entered into a compensation

BROKER RATINGS SUMMARY: Exane BNP And Bernstein Upgrade Morrisons

Director dealings: Chi-Med director's wife bags a bargain?

(ShareCast News) - The wife of Hutchison China MediTech (Chi-Med) director Christopher Nash has swooped into the market to pick up a few of the company's shares a after hearing good reports on the China-based biopharma outfit's recent interim results and bulging drug pipeline. Mrs Nash, wife of the

Chi-Med revenue ahead, but investments kill most income

(ShareCast News) - Hutchison China MediTech reported its interim results for the six months to 30 June on Tuesday, with group revenue up 27% to $104.5m, from $82.5m. The AIM-traded firm said net income attributable to Chi-Med was $0.5m, significantly down from $15.9m a year ago, reflecting a sharp i

Chi-Med expands TATTON Phase II trial

(ShareCast News) - Healthcare group Hutchison China MediTech (Chi-Med) announced on Monday the start of a Phase II expansion of its ongoing TATTON trial. The AIM-traded firm said the TATTON trial is evaluating the selective c-Met inhibitor savolitinib in epidermal growth factor receptor (EGFR) mutan

Hutchison China Expands Savolitinib Trials, Gets AstraZeneca Payment

UK advisers struggling with Chinese stock listings - survey

By Alasdair Pal and Patrick Graham LONDON, May 23 (Reuters) - Almost two-thirds of the advisory firms who assist in stock exchange listings in London say they are struggling to guide Chinese firms through the process, a survey showed, in the latest sign of problems with such initial public

Chi-Med launches fruquintinib trial in China

(ShareCast News) - Hutchison China MediTech announced on Friday that it has completed patient enrolment of FRESCO, its Phase III trial of fruquintinib in third-line locally advanced or metastatic colorectal cancer in China. The AIM-traded company said more than 300,000 new cases of CRC were diagnose

Hutchison China MediTech Completes Fruquintinib Trial Enrolment